DATROWAY^® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

DATROWAY® has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.